ENJournal of cystic fibrosis : official journal of the European Cystic Fibrosis Society | Sleep patterns and glycemia in adults with Cystic Fibrosis-Related Diabetes: a remote pilot study
Date: August 12, 2026
Classification: Frontiers
Recommend:
This study reveals a significant association between sleep onset latency and glycemic variability, suggesting that sleep health should be systematically assessed in the management of CFRD patients, providing actionable behavioral targets for the design of future intervention trials.
Literature Overview
The article titled 'Sleep patterns and glycemia in adults with Cystic Fibrosis-Related Diabetes: a remote pilot study', published in the 'Journal of cystic fibrosis: official journal of the European Cystic Fibrosis Society', systematically investigates the relationship between sleep characteristics and glycemic dynamics in adults with cystic fibrosis-related diabetes (CFRD) in real-world settings. Using a fully remote monitoring design combining continuous glucose monitoring (CGM), actigraphy, and standardized questionnaires, the study enables synchronized assessment of sleep and metabolic phenotypes. Results indicate that although most patients are on insulin therapy with acceptable HbA1c control, sleep quality is generally poor, and longer sleep onset latency is significantly associated with worse glycemic control. This study provides preliminary evidence for exploring sleep as an intervenable factor to improve metabolic outcomes in CFRD.Background Knowledge
Cystic fibrosis (CF) is an autosomal recessive disorder caused by mutations in the CFTR gene, leading to multi-organ dysfunction. With increased life expectancy, CFRD has become one of the most common comorbidities, affecting up to 50% of adult patients, and is closely associated with declining lung function and increased mortality. Current management of CFRD primarily relies on insulin therapy and nutritional support, yet frequent glucose fluctuations suggest under-recognized regulatory factors. Sleep disturbances are highly prevalent in CF patients due to multiple factors including nocturnal cough, dyspnea, gastroesophageal reflux, and treatment burden. Existing studies show that sleep deprivation and fragmentation can impair insulin sensitivity and exacerbate glycemic variability, indicating a potential key role of sleep in metabolic dysregulation in CFRD. However, previous studies largely relied on subjective reports, lacking synchronized, objective data on sleep and glucose. Therefore, this study leverages remote phenotyping technology to conduct synchronized, multidimensional assessments of sleep architecture and glycemic dynamics in CFRD patients within their natural living environments, aiming to identify potential intervenable sleep traits.
Methods and Core Experiments
The study employed a fully remote, 10-day observational cohort design, enrolling 30 clinically stable adult CFRD patients aged 18–79 years. All participants completed continuous glucose monitoring (using Dexcom G6 Pro), actigraphy monitoring (ActTrust 2), daily sleep diaries, 4-day dietary records, and standardized sleep questionnaires (including PSQI, ISI, STOP-Bang, and CH-RLSq) at home. Additionally, participants collected fingertip blood samples under video guidance for home HbA1c testing. This design avoids center effects and hospital disruptions, providing a true reflection of daily life. Key experiments included: 1) using CGM to obtain glycemic metrics such as TIR (70–180 mg/dL), TAR, and TBR; 2) combining actigraphy and sleep diaries to determine major sleep periods and calculate objective metrics including sleep latency, efficiency, and total duration; 3) assessing sleep quality, insomnia, sleep apnea, and restless legs syndrome risk via questionnaires. Data analysis used Spearman’s correlation test to explore relationships between sleep and glycemic metrics.Key Findings and Insights
Implications and Future Directions
This study opens new avenues for the comprehensive management of CFRD. In clinical practice, sleep screening should be integrated into routine care, especially for patients with sleep initiation difficulties, who may face higher metabolic risks. Future studies could build on these findings to conduct randomized controlled trials testing whether interventions such as cognitive behavioral therapy for insomnia (CBT-I) or light therapy to improve sleep onset can enhance TIR. Furthermore, the study validates the feasibility of fully remote phenotyping in rare disease research, offering a methodological template for multicenter, large-sample studies, thereby accelerating the development of precision medicine for CFRD.
Conclusion
Using an innovative remote monitoring strategy, this study is the first to synchronously assess sleep and glycemic dynamics in CFRD patients in real-world settings. It finds that despite most patients meeting glycemic control targets, sleep disorders are highly prevalent, and difficulty falling asleep is significantly associated with poorer glycemic stability. This finding underscores the potential role of sleep health in the metabolic management of CFRD, suggesting that clinical teams should systematically evaluate and intervene on sleep issues while optimizing insulin regimens. From bench to bedside, this study provides preliminary evidence for targeting sleep as a modifiable behavioral factor, advancing the shift from 'glucose control only' to a holistic 'metabolic-sleep health' management model. In the future, integrating wearable devices with digital health interventions may enable around-the-clock, personalized management of CFRD patients, ultimately improving long-term outcomes. This work not only deepens our understanding of the pathophysiology of CFRD but also provides a methodological paradigm for studying sleep-metabolism interactions in other chronic diseases.
